Drug Type Antibody drug conjugate (ADC) |
Synonyms BCG-026 |
Target |
Action antagonists, inhibitors |
Mechanism FAP antagonists(Fibroblast activation protein alpha antagonists), GPC1 inhibitors(Glypican-1 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Lung Cancer | Preclinical | United States | 22 Apr 2026 | |
| Pancreatic Cancer | Preclinical | China | 03 Apr 2026 |






